51 results about "Cardioplegias" patented technology

A method for closed-chest cardiac surgical intervention relies on viewing the cardiac region through a thoracoscope or other viewing scope and endovascularly partitioning the patient's arterial system at a location within the ascending aorta. The cardiopulmonary bypass and cardioplegia can be induced, and a variety of surgical procedures performed on the stopped heart using percutaneously introduced tools. The method of the present invention will be particularly suitable for forming coronary artery bypass grafts, where an arterial blood source is created using least invasive surgical techniques, and the arterial source is connected to a target location within a coronary artery while the patient is under cardiopulmonary bypass and cardioplegia.

The present invention provides a novel ergonomic handle for a retrograde coronary sinus catheter stylet. The handle is provided at a proximal end of a thin rod. In use, the stylet is inserted into a retrograde cardioplegia catheter. The stylet handle of the present invention extends from the proximal end of the catheter. The handle includes a generally flat, substantially planar body portion having a proximal end, a distal end and an axis extending from the proximal end to the distal end. A first concave pocket is provided at the distal end of the body on one side of the axis and a second concave pocket is provided at the distal end of the body on the opposite side of the axis. Each pocket has a plurality of surfaces against which at least one of the digits of a user may be placed to manipulate the position of the stylet, and thus the catheter. The handle is manipulated in a plane defined by the body so as to manipulate the stylet and the catheter. The body also has a third concave pocket which is proximate to the second pocket. At least one of the user's digits can grip the third pocket.

A disposable cartridge for use in extracorporeal blood perfusions systems that have a control unit for controlling the flow of fluids. The cartridge has a housing defining a plurality of internal passageways that connect to a cardiopulmonary circuit, a cardioplegia circuit and a suction circuit. The cartridge may be fitted with one or more of a bubble trap, a filter, and a valve.

An extracorporeal blood perfusion system includes a disposable assembly and a control unit having a control interface region. The interface region includes pump assemblies for selective pumping of venous blood, arterial blood, cardioplegia solution, suctioned blood and blood removed from the left ventricle. Valve assemblies control the flow of fluids through the assembly and to / from the patient and sensors monitor various fluid parameters including temperature and pressure within the various fluid circuits. The user interface is a functional screen interface for effecting the operation of the control unit and valve assemblies. The screen interface may be a touch screen having objects that corresponds to the component interface region. The display may be selectively controlled to provide graphic depictions of disposable assembly components with corresponding narrative instructions.

A cardioplegia catheter is configured to extend into the ascending aorta with a proximal portion of the shaft extending into a left chamber of the heart through a aortic valve and out of the heart through a penetration in a wall thereof. The cardioplegia catheter has an occlusion member configured to occlude the ascending aorta between the brachiocephalic artery and the coronary ostia. An arterial return cannula delivers oxygenated blood to the arterial system downstream of the occlusion member, while cardioplegic fluid is delivered through a lumen in the cardioplegia catheter upstream of the occlusion member to induce cardioplegic arrest.

A method for closed-chest cardiac surgical intervention relies on viewing the cardiac region through a thoracoscope or other viewing scope and endovascularly partitioning the patient's arterial system at a location within the ascending aorta. The cardiopulmonary bypass and cardioplegia can be induced, and a variety of surgical procedures performed on the stopped heart using percutaneously introduced tools. The method of the present invention will be particularly suitable for forming coronary artery bypass grafts, where an arterial blood source is created using least invasive surgical techniques, and the arterial source is connected to a target location within a coronary artery while the patient is under cardiopulmonary bypass and cardioplegia.

A method for closed-chest cardiac surgical intervention relies on viewing the cardiac region through a thoracoscope or other viewing scope and endovascularly partitioning the patient's arterial system at a location within the ascending aorta. The cardiopulmonary bypass and cardioplegia can be induced, and a variety of surgical procedures performed on the stopped heart using percutaneously introduced tools. The method of the present invention will be particularly suitable for forming coronary artery bypass grafts, where an arterial blood source is created using least invasive surgical techniques, and the arterial source is connected to a target location within a coronary artery while the patient is under cardiopulmonary bypass and cardioplegia

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and / or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

A microplegia console for controlling the delivery of cardioplegia to a patient, comprising an integrated display / touch screen for displaying cardioplegia information and patient information and allowing inputting of parameters via the display / touch screen into the console for computer-controlled perfusion of cardioplegia into the patient. The invention further comprises a method for delivery of cardioplegia to a patient, including defining and selecting a protocol from a displayed list and sequencing a series of the protocols. The invention also comprises a method for cardioplegia delivery to achieve aortic valve closure. Additionally, the invention comprises a method for activating an icon whereby, upon a first selection of the icon, displaying an indicia indicating that the icon has been first selected; and upon a second selection of the icon, activating the icon.

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and / or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

A system is disclosed for cannulating the vena cava of a patient during cardiopulmonary bypass procedures. Such cannulation is necessary for drainage of venous blood from the patient so that it may be oxygenated and pumped back to the patient to perfuse tissues during cardiac surgery and, more specifically, during periods of ischemic cardiac arrest or dysfunction. The device of the present invention not only provides venous drainage for cardiopulmonary bypass, but also performs the function of routing cardioplegic solution through the heart in the retrograde direction. Such cardioplegia provides protection to the heart during periods of ischemic cardiac arrest. This invention replaces a plurality of cannulae currently used for open-heart surgery, thus simplifying the surgical field and improving visibility of the heart. The device allows for the delivery of retrograde cardioplegia to the coronary circulation of both the right and the left side of the heart. The device further includes protection mechanisms to prevent overinflation or excessive pressurization of the right atrium during retrograde delivery of cardioplegia solution.

A cardioplegia occluder and methods of using the device during cardiac surgery are disclosed. The system typically includes a substantially rigid cannula with an occluder mounted on the distal region of the cannula that expands upon activation to occlude the aorta downstream of an infusion port which delivers cardioplegia solution to arrest the heart. Systems including cutting blades, blade guards, flanges, radiopaque markers and occluder aligners are also disclosed. In use, the distal end of the cannula is inserted through an incision into the aorta, the occluder is expanded and cardioplegia solution is infused upstream of the aorta to arrest the heart. The infusion port can alternately be used to aspirate cardioplegia or embolic debris or other unwanted material from the aorta.

Cardioplegia is delivered to a heart vessel by conducting the cardioplegia through an infusion lumen of a cannula. The cardioplegia communicates with a balloon disposed on a distal end of the cannula to cause the cardioplegia to inflate the balloon into sealing contact with a wall of the coronary sinus. The flow of cardioplegia is halted while preventing drainage of cardioplegia from the balloon, to maintain the balloon in its inflated state until such time as the flow of cardioplegia is resumed. Drainage of cardioplegia from the balloon is prevented by causing a valve to be shifted to a closed position blocking communication between the infusion lumen and the balloon. The valve can be shifted manually, or automatically in response to the halting of the delivery of cardioplegia.

The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, or to prolong the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of a Pyridyl-Substituted Porphyrin Compound.

The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, and methods for prolonging the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound.

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and / or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

A cardioplegia catheter system for delivery of a cardioplegia solution, comprising a cardioplegia catheter comprising an elongate tubular catheter body that defines a continuous central lumen and a flange that is connected to and extends therefrom an exterior surface of the catheter body, the flange defining a plurality of suture openings that extend therethrough the flange from a top surface to a bottom surface thereof. The cardioplegia system further comprising at least one stay suture and at least one suture capture stylet having a distal portion that is adapted to extend through one suture opening of the plurality of suture openings in the flange of the catheter body, wherein the distal portion of the rod has a shape that is adapted for slideably grasping a portion of the at least one stay suture.

The invention discloses an injective myocardial tissue engineering product basing on temperature responsive chitosan hydrogel and more particularly relates to liquid temperature responsive chitosan hydrogel which is used as stent material that is combined with seed cells from different sources, such as embryonic stem cells, mesenchymal stem cells, human fetal cadiacmyocytes, etc., and is injected and transplanted into the specific region of an animal myocardial infarction model for observing the condition of repairing the myocardial infarction region. Constructed by the stent material, the injective myocardial tissue engineering product can improve the retention rate and the survival rate of the seed cells, can promote the regeneration of myocardial tissues, can increase the wall thickness of the infarction region and can remold the shape of an original ventricular and improve the heart function. The product is provided with the injective character and is convenient for the treatment operation, thereby avoiding risks brought by the operations of cardioplegia arrest, extracorporeal circulation, etc. The injective myocardial tissue engineering product basing on the temperature responsive chitosan hydrogel has the advantages of simple operation process and mild implementation condition, provides a new product for the myocardial tissue engineering and has great significance for the clinical development of the tissue engineering myocardial treatment on heart diseases.

The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereofwhereinA is —CH2OHB and C are —OH:D isA and B are trans with respect to each other:B and C are cis with respect to each other:C and D are cis or trans with respect to each other:R1 is —H, -halo, —CN, —N(R2)2, —OR2, —SR2, —NHC(O)R2, —NHC(O)N(R2)2, —NHC(O)OR2, —C(O)OR2, —C(O)R2, —C(O)N(R2)2, —OC(O)N(R2)2, —C(halo)3, or —NO2;each R2 is independently —H, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle, —(CH2)n-(8- to 12-membered bicyclic heterocycle), —(CH2)n—(C3-C8 monocyclic cycloalkyl), —(CH2)n—(C3-C8 monocyclic cycloalkenyl), —(CH2)n—(C8-C12 bicyclic cycloalkyl), or —(CH2)n—(C8-C12 bicyclic cycloalkenyl);each n is an integer ranging from 0 to 6;each p is an integer ranging from 1 to 6; andeach q is an integer ranging from 1 to 6.

A method is disclosed for using fructose-1,6-diphosphate (FDP) to reduce and prevent two very serious problems caused by surgery that requires cardiopulmonary bypass. Before bypass begins, a liquid that contains FDP is intravenously injected into the patient, preferably over a period such as about 10 to 30 minutes, to allow the FDP to permeate in significant quantity into the heart and lungs while the heart is still beating. FDP can be added to the cardioplegia solution that is pumped through the heart to stop the heartbeat, and / or during bypass. This treatment was found to reduce two very important and serious problems that have unavoidably plagued CPB surgery in the past, which are: (1) elevated levels of pulmonary vascular resistance (PVR), which includes pulmonary hypertension; and (2) high occurrence rates for atrial fibrillation. Prior to this discovery, there has never been any satisfactory treatment which could reduce the severity and occurrence rates for these two major problems. FDP also can be co-administered in this manner, along with (1) a buffering or alkalizing agent that counteracts acidosis, such as sodium bicarbonate or THAM, and / or (2) a drug that reduces the formation of lactic acid, such as dichloroacetate.

Fructose-1,6-diphosphate (FDP) is used to treat patients who are undergoing coronary artery bypass grafting (CABG) surgery. Before cardiopulmonary bypass begins, a liquid that contains FDP is intravenously infused in the patient, preferably for about 10 to 30 minutes, to allow the FDP to enter the heart and lung tissue while the heart is still beating. FDP can also be added to cardioplegia solution; in addition, FDP can be injected after bypass is terminated, but if post-bypass injection is used, steps should be taken to avoid excess lactic acid accumulation, which appears to increase the risk of atrial fibrillation. To prevent or control lactic acidosis, a buffering or alkalizing agent, such as sodium bicarbonate, or an agent which reduces lactic acid formation, such as dichloroacetate, can be used. In double-blinded trials, this use of FDP substantially reduced heart damage and improved overall outcomes, as shown by lower levels of creatine kinase in blood, improvements in pumping performance, reduced requirements for vasodilator and inotropic drugs, and shorter stays in intensive care units. Certain dosages also reduced the likelihood of atrial fibrillation; however, FDP at high dosages increased the likelihood of A-fib. FDP also helped reduce pulmonary vascular resistance (PVR); this is an important finding, since pulmonary hypertension following cardiopulmonary bypass is a very difficult and often intractable problem, and is a contributing factor in nearly all deaths following CPB surgery.

This invention is a single, multichannel catheter useful for extracorporeal circulation of blood to a patient undergoing cardiovascular treatments or surgery. The catheter has three independent channels and an expandable balloon at one end of the catheter. The first channel (34) is the largest and is of a size that allows for delivery of blood to a patient in an amount sufficient to maintain the patient's metabolism and perfusion throughout the treatment or surgery. A second channel (36), smaller than the first, is integrated into the wall of the first channel, and is suitable for delivering a biologically active fluid (e.g., for cardioplegia) to the heart and / or venting the left heart. A third channel (38), also smaller than the first, is integrated into the wall of the first channel, and suitable for delivering a fluid to the balloon for its expansion when positioned in the ascending aorta to occlude the flow of blood to the heart. It is important that the first channel accounts for at least about 70% of the total channel volume. The catheter provides an improved means of performing cardiovascular surgery on a patient using a cardiopulmonary machine for extracorporeal circulation of blood. The catheter is particularly useful for cardiac surgery. The multichannel catheter is best prepared using an extrusion molding technique.

Cardioplegia is delivered to a heart vessel by conducting the cardioplegia through an infusion lumen of a cannula. The cardioplegia communicates with a balloon disposed on a distal end of the cannula to cause the cardioplegia to inflate the balloon into sealing contact with a wall of the coronary sinus. The flow of cardioplegia is halted while preventing drainage of cardioplegia from the balloon, to maintain the balloon in its inflated state until such time as the flow of cardioplegia is resumed. Drainage of cardioplegia from the balloon is prevented by causing a valve to be shifted to a closed position blocking communication between the infusion lumen and the balloon. The valve can be shifted manually, or automatically in response to the halting of the delivery of cardioplegia.

The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also therapeutic methods and apparatuses for hypoxic / ischemic injury, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the polychalcogenide compositions described.

A single, multichannel catheter useful for extracorporeal circulation of blood to a patient undergoing cardiovascular treatments or surgery. The catheter has three independent channels and an expandable balloon at one end of the catheter. The first channel is the largest and is of a size that allows for delivery of blood to a patient in an amount sufficient to maintain the patient's metabolism and perfusion throughout the treatment or surgery. A second channel, smaller than the first, is integrated into the wall of the first channel and is suitable for delivering a biologically active fluid (e.g., for cardioplegia) to the heart and / or venting the left heart. A third channel, also smaller than the first, is integrated into the wall of the first channel and suitable for delivering a fluid to the balloon for its expansion when positioned in the ascending aorta to occlude the flow of blood to the heart. It is important that the first channel accounts for at least about 70% of the total channel volume. The catheter provides an improved means of performing cardiovascular surgery on a patient using a cardiopulmonary machine for extracorporeal circulation of blood. The catheter is particularly useful for cardiac surgery. The multichannel catheter is best prepared using an extrusion molding technique.

A system for delivering blood, cardioplegia solution, and other medications or fluids in a pulsatile flow pattern to a patient during cardiopulmonary bypass is disclosed. In a preferred embodiment, a pumping apparatus having at least one chamber is utilized in which a pumping action is achieved by compressing one of the chambers with a piston mechanism, while allowing the other chamber to fill with fluid via retracting its respective piston. The instantaneous flow rate of either of the chambers is determined by the speed of the piston. In a preferred embodiment, a pulsatile flow of fluid is achieved by cyclically alternating the velocity of the piston between two different speeds. A desired average flow rate and / or delivery pressure and / or constant pulse pressure is maintained by adjusting the alternating velocities at the desired frequency and duty cycle. The calculations necessary to obtain a desired average flow rate are performed by a microprocessor, which also controls the movement of the pistons.

The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, or to prolong the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of a Pyridyl-Substituted Porphyrin Compound.